Inactive Instrument

Yumanity Therapeutics

Equities

YMTX

US98872L1026

Yumanity Therapeutics Appoints Ajay Verma as Executive Vice President and Head of Research & Development

April 13, 2021 at 08:00 am EDT

Yumanity Therapeutics announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development. He was most recently the Executive Vice President of Research and Experimental Medicine at Codiak Biosciences where he advanced the company’s novel precision exosome platform. Before this role, he was Chief Medical Officer at United Neuroscience focusing on vaccines for neurological disorders.

Latest news about Yumanity Therapeutics

Kineta's Shares Gain Momentum on Nasdaq Debut Following Yumanity Therapeutics Reverse Merger Completion	22-12-19	MT
Kineta, Yumanity Therapeutics Complete Reverse Merger	22-12-19	MT
Yumanity Therapeutics Inc.(NasdaqCM:KA) dropped from NASDAQ Composite Index	22-12-16	CI
Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	22-12-15	CI
Sector Update: Health Care Stocks Stage Small Recovery Late	22-12-14	MT
Sector Update: Health Care	22-12-14	MT
Top Midday Decliners	22-12-14	MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	22-12-14	MT
Investors Remain Sidelined in Premarket Trading Ahead of Fed Decision Wednesday	22-12-14	MT
Top Premarket Decliners	22-12-14	MT
Daehan Green Power Corporation agreed to acquire 5.58% stake in Yumanity Therapeutics, Inc. for KRW 1.3 billion.	22-12-05	CI
Sector Update: Healthcare Stocks Slide Monday but Outperform Most Sectors	22-12-05	MT
Sector Update: Health Care Stocks Pulled Lower by Sinking Biotechs	22-12-05	MT
Yumanity Therapeutics to Pay Special Cash Dividend Related to Planned Asset Sale, Kineta Merger -- Shares Rise	22-12-05	MT
Economic Data Outlook Prompts Weak Open for US Equities	22-12-05	MT
Top Premarket Gainers	22-12-05	MT
Yumanity Therapeutics Declares Special Dividend, Payable in Cash on or Before December 29, 2022	22-12-05	CI
Yumanity Therapeutics Inc. announced that it has received $7.500001 million in funding from Growth & Value Development Co., Ltd.	22-12-04	CI
Yumanity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Yumanity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Earnings Flash (YMTX) YUMANITY THERAPEUTICS Reports Q2 Revenue $1.66M	22-08-04	MT
Sector Update: Health Care Stocks Slip Amid Losses for Biotechs	22-06-06	MT
Sector Update: Health Care Stocks Edging Higher This Afternoon	22-06-06	MT
Sector Update: Health Care	22-06-06	MT
US Stocks Weakening in Midday Trading but Largely Staying on Positive Ground	22-06-06	MT

Chart Yumanity Therapeutics

Duration

Period

More charts

Company Profile

Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's pipeline consists of programs focused on Parkinson's disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. The Company's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The Company's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.

Sector

More about the company